 HOUSTON, March 30, 2021 PRNewswire -- Moleculin Biotech, Inc., Nasdaq: MBRX Moleculin or the Company, a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the U.S. Food and Drug Administration FDA has approved its request for Fast Track Designation for its drug, Annamycin, for the treatment of soft tissue sarcoma STS lung metastases. We are pleased to receive our second Fast Track Designation from the FDA for Annamycin. 